Current Concepts and Medical Management for Patients with Radiographic Axial Spondyloarthritis

키워드

참고문헌 (72)

1. Olivieri I, "Seronegative spondyloarthritides", Best Pract Res Clin Rheumatol, 16, pp.723~739 (2002)[DOI]
2. Braun J, "Ankylosing spondylitis", Lancet, 369, pp.1379~1390 (2007)[DOI]
3. Khan MA, "Ankylosing spondylitis : a dual perspective of current issues and challenges", J Rheumatol Suppl, 78, pp.1~3 (2006)
4. Zeng QY, "Ankylosing spondylitis in Shantou, China : 15 years'clinical experience", J Rheumatol, 30, pp.1816~1821 (2003)
5. Rudwaleit M, "The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis(part II) : validation and final selection", Ann Rheum Dis, 68, pp.777~783 (2009)[DOI]
6. Park JS, "Trends in the prevalence and incidence of ankylosing spondylitis in South Korea, 2010-2015 and estimated differences according to income status", Sci Rep, 8, pp.7694~ (2018)[DOI]
7. Kwon SR, "The epidemiology and treatment of ankylosing spondylitis in Korea", J Rheum Dis, 29, pp.193~199 (2022)[DOI]
8. Hukuda S, "Spondyloarthropathies in Japan : nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society", J Rheumatol, 28, pp.554~559 (2001)
9. Chou CT, "Prevalence of rheumatic diseases in Taiwan : a population study of urban, suburban, rural differences", J Rheumatol, 21, pp.302~306 (1994)
10. Dans LF, "The prevalence of rheumatic diseases in a Filipino urban population : a WHO-ILAR COPCORD Study. World Health Organization. International League of Associations for Rheumatology. Community Oriented Programme for the Control of the Rheumatic Diseases", J Rheumatol, 24, pp.1814~1819 (1997)
11. Pedersen SJ, "The pathogenesis of ankylosing spondylitis : an update", Curr Rheumatol Rep, 21, pp.58~ (2019)
12. Siebert S, "Why did IL-23p19 inhibition fail in AS : a tale of tissues, trials or translation?", Ann Rheum Dis, 78, pp.1015~1018 (2019)[DOI]
13. Braun J, "Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors", Arthritis Rheum, 41, pp.58~67 (1998)[DOI]
14. Tedeschi V, "ERAP1 and ERAP2 haplotypes influence suboptimal HLA-B*27 : 05-restricted anti-viral CD8+ T cell responses cross-reactive to self-epitopes", Int J Mol Sci, 24, pp.13335~ (2023)[DOI]
15. Babaie F, "Inhibition of ERAP1represses HLA-B27 free heavy chains expression on polarized macrophages and interrupts NK cells activation and function from ankylosing spondylitis", Clin Immunol, 248, pp.109268~ (2023)[DOI]
16. Clunie G, "Loss and gain of bone in spondyloarthritis : what drives these opposing clinical features?", Ther Adv Musculoskelet Dis, 12, pp.1759720X20969260~ (2020)[DOI]
17. Baraliakos X, "Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept : clinical and magnetic resonance imaging data", Arthritis Rheum, 53, pp.856~863 (2005)[DOI]
18. Zhao Z, "Correlation between magnetic resonance imaging(MRI)findings and the new bone formation factor Dkk-1 in patients with spondyloarthritis", Clin Rheumatol, 38, pp.465~475 (2019)[DOI]
19. Akhondi H, "StatPearls" (2023), StatPearls Publishing
20. Taitt HA, "Spondyloarthritides", Immunol Allergy Clin North Am, 43, pp.593~612 (2023)[DOI]
21. Machado P, "Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis", Ann Rheum Dis, 69, pp.1465~1470 (2010)[DOI]
22. Taurog JD, "Ankylosing spondylitis and axial spondyloarthritis", N Engl J Med, 374, pp.2563~2574 (2016)[DOI]
23. Rosenbaum JT, "Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease", Clin Rheumatol, 34, pp.999~1002 (2015)[DOI]
24. Van Praet L, "Microscopic gut inflammation in axial spondyloarthritis : a multiparametric predictive model", Ann Rheum Dis, 72, pp.414~417 (2013)[DOI]
25. Vinker Shuster M, "Ischemic heart disease and ankylosing spondylitis-assessing the role of inflammation", Clin Rheumatol, 37, pp.1053~1058 (2018)[DOI]
26. Rudwaleit M, "The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general", Ann Rheum Dis, 70, pp.25~31 (2011)[DOI]
27. Goie The HS, "Evaluation of diagnostic criteria for ankylosing spondylitis : a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis", Br J Rheumatol, 24, pp.242~249 (1985)[DOI]
28. van der Linden S, "Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria", Arthritis Rheum, 27, pp.361~368 (1984)[DOI]
29. Poddubnyy D, "Similarities and differences between nonradiographic and radiographic axial spondyloarthritis : a clinical, epidemiological and therapeutic assessment", Curr Opin Rheumatol, 26, pp.377~383 (2014)[DOI]
30. Sherlock JP, "IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8-entheseal resident T cells", Nat Med, 18, pp.1069~1076 (2012)[DOI]
31. Kojima H, "The modified Schober's test and ankylosing spondylitis", QJM, 115, pp.181~182 (2022)[DOI]
32. Amjad F, "Reliability of modified-modified Schober’s test for the assessment of lumbar range of motion", J Pak Med Assoc, 72, pp.1755~1759 (2022)[DOI]
33. Grubisić F, "Osteoporosis, spinal mobility and chest expansion index in patients with ankylosing spondylitis", Coll Antropol, 38, pp.63~68 (2014)
34. Michielsens C, "Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treatto-target axial spondyloarthritis cohort: a cross-sectional study", Scand J Rheumatol (2023)[DOI]
35. Kiltz U, "Clinically relevant deficits in performance tests in patients with axial spondyloarthritis", J Rheumatol, 50, pp.351~358 (2023)[DOI]
36. Yoo SJ, "Differential imaging features of widening and pseudo-widening of the sacroiliac joints", Arthritis Rheumatol, 70, pp.755~ (2018)[DOI]
37. Coates LC, "The phenotype of axial spondyloarthritis : is it dependent on HLA-B27 status?", Arthritis Care Res(Hoboken), 73, pp.856~860 (2021)[DOI]
38. Rudwaleit M, "Defining active sacroiliitis on magnetic resonance imaging(MRI)for classification of axial spondyloarthritis : a consensual approach by the ASAS", OMERACT MRI group, 2009, pp.68, 1520~1527
39. Sieper J, "The Assessment of SpondyloArthritis international Society(ASAS)handbook : a guide to assess spondyloarthritis", Ann Rheum Dis, 68(Suppl 2), pp.ii1~ii44 (2009)[DOI]
40. Moon KH, "Medical treatment of ankylosing spondylitis", Hip Pelvis, 26, pp.129~135 (2014)[DOI]
41. Ward MM, "2019 Update of the American College of Rheumatology", Spondylitis Association of America, Arthritis Rheumatol, pp.2019, 71[DOI]
42. Ramiro S, "ASAS-EULAR recommendations for the management of axial spondyloarthritis : 2022 update", Ann Rheum Dis, 82, pp.19~34 (2023)[DOI]
43. Zhu W, "Ankylosing spondylitis : etiology, pathogenesis, and treatments", Bone Res, 7, pp.22~ (2019)[DOI]
44. Kroon FP, "Non-steroidal anti-inflammatory drugs(NSAIDs)for axial spondyloarthritis(ankylosing spondylitis and non-radiographic axial spondyloarthritis)", Cochrane Database Syst Rev, 2015, pp.CD010952~ (2015)[DOI]
45. Deodhar A, "Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis", Semin Arthritis Rheum, 47, pp.343~350 (2017)[DOI]
46. Tian C, "Efficacy and safety of IL inhibitors, TNF-α inhibitors, and JAK inhibitors in patients with ankylosing spondylitis : a systematic review and Bayesian network meta-analysis", Ann Transl Med, 11, pp.178~ (2023)[DOI]
47. Lee YH, "Janus kinase inhibitors for treating active ankylosing spondylitis : a meta-analysis of randomized controlled trials", Z Rheumatol, 81, pp.71~76 (2022)[DOI]
48. Khalessi AA, "Medical management of ankylosing spondylitis", Neurosurg Focus, 24, pp.E4~ (2008)[DOI]
49. Song IH, "Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs", Arthritis Rheum, 58, pp.929~938 (2008)[DOI]
50. "Z Rheumatol", 2022, 198~204, 10.1007[DOI]
51. Qiao M, "Radiologic and pathological investigation of pseudarthrosis in ankylosing spondylitis : distinguishing between inflammatory and traumatic etiology", J Rheumatol, 46, pp.259~265 (2019)[DOI]
52. Kroon F, "Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis", Ann Rheum Dis, 71, pp.1623~1629 (2012)[DOI]
53. Sieper J, "Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine : results from a randomised multicentre trial(ENRADAS)", Ann Rheum Dis, 75, pp.1438~1443 (2016)[DOI]
54. Chen J, "Sulfasalazine for ankylosing spondylitis", Cochrane Database Syst Rev, 11, pp.CD004800~ (2014)[DOI]
55. Haibel H, "Use of methotrexate in patients with ankylosing spondylitis", Clin Exp Rheumatol, 28(5 Suppl 61), pp.S128~S131 (2010)
56. Yang Z, "Efficacy evaluation of methotrexate in the treatment of ankylosing spondylitis using meta-analysis", Int J Clin Pharmacol Ther, 52, pp.346~351 (2014)[DOI]
57. Chen J, "Methotrexate for ankylosing spondylitis", Cochrane Database Syst Rev, 4, pp.CD004524~ (2006)[DOI]
58. Gonzalez-Lopez L, "Efficacy of methotrexate in ankylosing spondylitis : a randomized, double blind, placebo controlled trial", J Rheumatol, 31, pp.1568~1574 (2004)
59. Cao Z, "Optimal biologic drugs for the treatment of ankylosing spondylitis : results from a network meta-analysis and network metaregression", Biomed Res Int, 2022, pp.8316106~ (2022)[DOI]
60. van den Berg R, "First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs : a systematic literature review for the ASAS", EULAR management recommendations in ankylosing spondylitis, 2012, pp.51, 1388~1396
61. Park JS, "National pharmacological treatment trends for ankylosing spondylitis in South Korea : a National Health Insurance Database study", PLoS One, 15, pp.e0240155~ (2020)[DOI]
62. Min HK, "Clinical efficacy of alternative TNF inhibitor and secukinumab between primary nonresponder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis", Mod Rheumatol, 33, pp.194~201 (2023)[DOI]
63. Joshi R, "Characterization of patients with ankylosing spondylitis receiving secukinumab and reasons for initiating treatment : a US physician survey and retrospective medical chart review", Drugs Real World Outcomes, 6, pp.1~9 (2019)[DOI]
64. Wroński J, "Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors : a cross-sectional study", Int J Clin Pharm, 41, pp.864~871 (2019)[DOI]
65. Kim HW, "Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis and psoriasis treated with IL-17 and TNF-α inhibitors : a nationwide nested case-control analysis", Clin Exp Rheumatol, 41, pp.1491~1499 (2023)[DOI]
66. Torres T, "Drug survival of IL-12", 23, IL-17 and IL-23 inhibitors for psoriasis treatment : a retrospective multi-country, multicentric cohort study, 2021, pp.22, 567~579
67. Lee HI, "IL-6 activates pathologic Th17 cell via STAT 3 phosphorylation in inflammatory joint of ankylosing spondylitis", Biochem Biophys Res Commun, 620, pp.69~75 (2022)[DOI]
68. van der Heijde D, "Tofacitinib in patients with ankylosing spondylitis : a phase II, 16-week, randomised, placebo-controlled, dose-ranging study", Ann Rheum Dis, 76, pp.1340~1347 (2017)[DOI]
69. van der Heijde D, "Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis(TORTUGA) : results from a randomised, placebo-controlled, phase 2 trial", Lancet, 392, pp.2378~2387 (2018)[DOI]
70. Namour F, "Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor", Br J Clin Pharmacol, 84, pp.2779~2789 (2018)[DOI]
71. Honda S, "The safety of baricitinib in patients with rheumatoid arthritis", Expert Opin Drug Saf, 19, pp.545~551 (2020)[DOI]
72. Hoisnard L, "Adverse events associated with JAK inhibitors in 126, 815 reports from the WHO pharmacovigilance database", Sci Rep, 12, pp.7140~ (2022)[DOI]

관련 논문AI추천